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Abstract
Background Attention-deficit/hyperactivity disorder
(ADHD) is increasingly recognized as a persistent disorder
requiring long-term management.
Objectives Our objective was to evaluate the 2-year safety
and efficacy of lisdexamfetamine dimesylate (LDX) in
children and adolescents with ADHD.
Methods Participants (aged 6–17 years) with ADHD
received open-label, dose-optimized LDX 30, 50, or
70 mg/day for 104 weeks. Safety monitoring included
treatment-emergent adverse events (TEAEs), vital signs,
electrocardiography, and growth. The TEAEs decreased
appetite, weight decrease, insomnia events (including
insomnia, initial insomnia, middle insomnia, and terminal
insomnia), headache, and psychiatric TEAEs were pre-
defined as being of special interest. Efficacy was assessed
as a secondary objective using the ADHD Rating Scale IV
(ADHD-RS-IV), the Clinical Global Impressions-Im-
provement (CGI-I) scale, and the CGI-Severity (CGI-S)
scale.
Results Of 314 participants enrolled, 191 completed the
study. TEAEs were reported in 89.8% of participants, led
to discontinuation in 12.4%, and were reported as serious
in 8.9%. TEAEs that were reported by C5% of participants
and considered by investigators as related to LDX were
decreased appetite (49.4%), weight decrease (18.2%),
insomnia (13.1%), initial insomnia (8.9%), irritability
(8.6%), nausea (6.7%), headache (5.7%), and tic (5.1%).
The median time to first onset and duration, respectively, of
TEAEs of special interest were as follows: decreased
appetite, 13.5 and 169.0 days; weight decrease, 29.0 and
225.0 days; insomnia, 17.0 and 42.8 days; and headache,
22.0 and 2.0 days. Reports of decreased appetite, weight
decrease, insomnia, and headache were highest in the first
4–12 weeks. Psychiatric TEAEs were infrequent: psy-
chosis and mania (n = 1), suicidal events (suicidal idea-
tion, n = 2; suicide attempt, n = 1), and aggression events
(aggression, n = 14; anger, n = 2; hostility, n = 1). At the
last on-treatment assessment (LOTA), mean increases from
baseline in vital signs were as follows: pulse rate, 7.0 bpm
(95% confidence interval [CI] 5.7–8.2); systolic blood
pressure (SBP), 3.4 mmHg (95% CI 2.2–4.5); and diastolic
blood pressure (DBP), 3.2 mmHg (95% CI 2.2–4.2). Pre-
defined thresholds for a potentially clinically important
(PCI) high pulse rate were met at one or more visits by 22
participants (7.0%), for PCI high SBP were met by 45
children (22.4%) and 17 adolescents (15.2%), and for PCI
high DBP were met by 78 children (38.8%) and 24
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adolescents (21.4%). The mean QT interval corrected using
Fridericia’s formula (QTcF) decreased from baseline to
LOTA (-0.6 ms [95% CI -2.3 to 1.2]; range -50 to
?53). Mean changes in growth from baseline to LOTA
were weight, 2.1 kg (95% CI 1.5–2.8); height, 6.1 cm
(95% CI 5.6–6.7); and body mass index (BMI), -0.5 kg/
m2 (95% CI -0.7 to -0.3). There was a general shift to
lower z score categories for height, weight, and BMI from
baseline to LOTA. The mean change in ADHD-RS-IV
from baseline to LOTA was -25.8 (95% CI -27.0 to
-24.5) for total score, -12.6 (95% CI -13.4 to -11.9) for
the hyperactivity/impulsivity subscale score, and -13.1
(95% CI -13.8 to -12.4) for the inattention subscale
score. At LOTA, 77.9% of participants had a CGI-I score
of 1 or 2. In addition, 77.3 and 69.2% of participants were
classified as treatment responders, based on a CGI-I score
of 1 or 2 and a C30% or C50% reduction from baseline in
ADHD-RS-IV total score, respectively.
Conclusions The safety profile of LDX in this longer-term
study was similar to that reported in previous studies. The
efficacy of LDX was maintained throughout the 2-year
study period.
ClinicalTrials.gov Identifier NCT01328756.
Key Points
This 2-year clinical study provides the most
comprehensive assessment to date of the long-term
safety of lisdexamfetamine dimesylate (LDX) in
children and adolescents with attention-deficit/
hyperactivity disorder (ADHD).
The observed effects of LDX on treatment-emergent
adverse events, vital signs, and growth were
consistent with findings from previous short-term
randomized controlled trials of LDX; no new safety
signals were reported.
LDX treatment was associated with improvements in
ADHD symptoms that were maintained for the
2-year duration of the study.
1 Introduction
Attention-deficit/hyperactivity disorder (ADHD) is a
common neurobehavioral disorder associated with high
levels of functional impairment and reduced quality of life
[1]. The mean worldwide prevalence of ADHD in children
and adolescents is estimated to be 5.3%, and, although
symptoms may ameliorate with time, impairing difficulties
persist into adulthood in 50–66% of patients [2–6].
Psychostimulants, including methylphenidate and
amphetamines, are commonly prescribed pharmacological
treatments for ADHD [7]. Lisdexamfetamine dimesylate
(LDX) is an amphetamine-based prodrug that, following
oral administration, is absorbed into the blood and enzy-
matically hydrolyzed to release therapeutically active d-
amphetamine [8–10]. The short-term efficacy and safety of
LDX have been demonstrated in children, adolescents, and
adults in several pivotal, randomized, double-blind, pla-
cebo-controlled clinical trials in the USA and Europe
[11–16]. The safety profile of LDX has been consistent
across studies, and the range of observed adverse events
(AEs), including decreased appetite, weight loss, and
insomnia, has been typical of those observed with other
psychostimulant ADHD medications [17].
Previous longer-term, open-label studies conducted in
the USA have shown that LDX reduces the core symptoms
of ADHD for up to 12 months and has a longer-term safety
profile similar to that observed in short-term LDX studies
[18–20]. Owing to the nature of AEs commonly associated
with stimulant medications, clinical practice guidelines
recommend that patients receiving long-term stimulant
medication are monitored regularly for height, weight, and
cardiovascular parameters [21]. Here, we report primary
results from the first 2-year open-label study of LDX in
Europe (SPD489-404; ClinicalTrials.gov identifier:
NCT01328756). This is currently the longest LDX clinical
study to be performed and was designed to include a
comprehensive battery of safety assessments, thereby pro-
viding the most in-depth evaluation to date of the long-term
safety and efficacy of LDX in children and adolescents
with ADHD.
2 Method
SPD489-404 was a phase IV, multicenter, open-label,
2-year study of the long-term safety and efficacy of LDX in
children and adolescents with ADHD. The study was
conducted in accordance with current applicable regula-
tions, International Conference on Harmonization Good
Clinical Practice Guideline E6 (1996), EU Clinical Trials
Directive 2001/20/EC (2001) and its updates, and local
ethical and legal requirements. The study protocol was
approved by an independent ethics committee/institutional
review board and regulatory agency in each center (as
appropriate). Each patient’s parent/legal guardian provided
written informed consent, and assent was obtained from
each participant (as applicable) before they took part in the
study. The study was conducted between 7 July 2011 and
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30 September 2014 at 35 sites in ten European countries
(Belgium, Germany, Hungary, Italy, Netherlands, Poland,
Romania, Spain, Sweden, and the UK).
2.1 Participants
Children (aged 6–12 years) and adolescents (aged
13–17 years) were either enrolled directly or had taken part
in a previous LDX study (ClinicalTrials.gov identifiers:
NCT01106430 [22], NCT00763971 [14], and
NCT00784654 [23]). Eligible individuals had a primary
diagnosis of ADHD based on Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition—Text Revi-
sionTM (DSM-IV-TR) criteria and a baseline ADHD Rating
Scale IV (ADHD-RS-IV) total score C28. Participants
were excluded if they had been terminated from a previous
LDX study for protocol non-adherence or non-compliance
or had experienced an AE leading to discontinuation, a
medication-related serious AE, or a clinically significant
AE in a previous LDX study. Patients whose current
ADHD medication provided effective control of symptoms
with acceptable tolerability were also excluded. Additional
inclusion and exclusion criteria are described in the Elec-
tronic Supplementary Material (ESM) 1.
2.2 Study Design
SPD489-404 consisted of three phases: 3–42-day screening
and washout; 104-week open-label treatment (4 weeks of
dose optimization and 100 weeks of dose maintenance);
and 28–30-day safety follow-up (Fig. 1). LDX was
administered as a once-daily morning dose. Dose opti-
mization (weeks 1–4) continued until an ‘‘acceptable’’
response was obtained, which was defined in previous
dose-optimized studies of LDX as a C30% reduction in
ADHD-RS-IV total score from baseline and a Clinical
Global Impressions-Improvement (CGI-I) score of 1 (very
much improved) or 2 (much improved) with tolerable side
effects [14, 16, 20, 22–24]. Dose adjustments could be
made throughout the dose-maintenance phase.
2.3 Safety
The primary objective of the study was to evaluate the
long-term tolerability and safety of LDX based on treat-
ment-emergent AEs (TEAEs), vital signs (single mea-
surements of sitting systolic blood pressure [SBP], diastolic
blood pressure [DBP], and pulse taken after 5 min of rest),
and electrocardiogram (ECG) parameters. TEAEs were
defined as AEs that started or worsened after the first dose
of LDX and up to the third day after treatment cessation.
TEAEs were coded using version 14.1 of the Medical
Dictionary for Regulatory Activities (MedDRA). The
sponsor required any new onset of seizures, loss of con-
sciousness, or syncope to be reported as a serious TEAE,
and defined psychiatric TEAEs (psychosis, mania, suicidal
events, and aggression events) as being of special interest.
Based on their reported association with stimulant treat-
ment, the TEAEs decreased appetite, weight decreased
(hereafter referred to as weight decrease), insomnia events
(including insomnia, initial insomnia, middle insomnia,
and terminal insomnia) and headache were also defined as
being of special interest. AE data were collected via
questions such as ‘‘have you had any health problems since
your last visit’’ at each study visit. It should be noted that
the TEAE weight decrease was based on perceived weight
loss rather than actual measurements of weight.
Additional safety assessments included height, weight,
and clinical laboratory measurements (biochemistry,
hematology, and urinalysis). Height, weight, and body
mass index (BMI) z scores were derived using the Centers
for Disease Control and Prevention growth charts [25].
Potentially clinically important (PCI) thresholds for high
pulse (C110 bpm), SBP (C125 mmHg in children and
C135 mmHg in adolescents), DBP (C80 mmHg in chil-
dren and C85 mmHg in adolescents), QT interval cor-
rected using Fridericia’s formula (QTcF; C450 ms), and
changes in weight (C7% change from baseline) were pre-
defined by the sponsor, based on clinical experience.
Psychiatric safety was monitored using the Brief Psy-
chiatric Rating Scale for Children (BPRS-C) and the
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Columbia-Suicide Severity Rating Scale (C-SSRS). The
BPRS-C is an investigator-rated 21-item scale that assesses
behavior disorders, depression, thinking disturbance, psy-
chomotor excitation, withdrawal retardation, anxiety, and
organicity using a 7-point Likert scale, from ‘not present’
(0 points) to ‘extremely severe’ (6 points) [26]. The
C-SSRS is a semi-structured interview that captures the
occurrence, severity, and frequency of suicide-related
thoughts and behaviors [27]. Neurocognition and sexual
development were monitored using the Cambridge Neu-
ropsychological Test Automated Battery [28] and Tanner
staging [29], respectively (Coghill DR et al. unpublished
data and Banaschewski T et al. unpublished data).
2.4 Efficacy
Efficacy was assessed as a secondary objective using the
investigator-administered ADHD-RS-IV, CGI-I, and CGI-
Severity (CGI-S) scales [30, 31]. The ADHD-RS-IV con-
sists of 18 items grouped into two subscales, ‘‘hyperac-
tivity/impulsivity’’ and ‘‘inattention’’, designed to reflect
current symptomatology based on DSM-IV-TR criteria.
Each item is scored from 0 (no symptoms) to 3 (severe
symptoms), giving a total possible score of 0–54. The CGI-
S rates ADHD severity using a 7-point scale ranging from
1 (normal, not at all ill) to 7 (among the most extremely
ill). The CGI-I scale rates patient improvement, relative to
baseline CGI-S, on a 7-point scale from 1 (very much
improved) to 7 (very much worse). Individuals with a CGI-
I score of 1 or 2 were categorized as improved.
Responder analyses were also performed, in which a
clinically relevant response was defined using two stan-
dards: (1) C30% reduction in ADHD-RS-IV total score
from baseline and a CGI-I score of 1 or 2, and (2) C50%
reduction in ADHD-RS-IV total score from baseline and a
CGI-I score of 1 or 2.
2.5 Data Analysis
In this open-label, uncontrolled study, the target enrollment
of approximately 300 participants was not based on sta-
tistical considerations. Safety analyses were performed
using the safety population, defined as all enrolled partic-
ipants who received at least one dose of LDX during the
study.
Efficacy analyses were performed using the full analysis
set (FAS), defined as all participants who had at least one
on-treatment post-baseline efficacy assessment. ADHD-
RS-IV and CGI-I scores were summarized for each visit
and for the last on-treatment assessment (LOTA) using
observed values. Changes from baseline to LOTA in
ADHD-RS-IV scores were assessed using a two-sided,
one-sample t test at a 0.05 significance level.
3 Results
3.1 Patient Disposition and Demographics
All 314 enrolled participants received at least one dose of
LDX and were included in the safety population (Fig. 2).
Of these, 124 (39.5%) had participated in an antecedent
LDX study and 190 (60.5%) were directly enrolled. In
total, 299 participants (95.2%) were included in the FAS.
Of the 15 individuals excluded from the FAS, one did not
have a post-baseline efficacy assessment and 14 partici-
pants were excluded on the basis of a serious breach of
Good Clinical Practice (GCP) compliance at a single study
site. The breach of GCP was identified by the sponsor
during a monitoring visit for a different study at the site; as
a precaution, the sponsor also discontinued participants
from all other studies at the site, including SPD489-404. In
total, 191 participants (60.8%) completed all visits for
SPD489-404. The primary recorded reasons for early dis-
continuation were withdrawal by the participant (13.1%),
AEs (12.4%), other (9.2%), lost to follow-up (1.6%),
investigator-perceived lack of efficacy (1.6%), and proto-
col deviations (1.3%). Baseline demographic data are
summarized in Table 1, and further information is provided
in Table S1 in the ESM.
3.2 Lisdexamfetamine Dimesylate Dosing
and Exposure
The mean average daily dose of LDX was 51.08 mg (s-
tandard deviation [SD] 14.352), and the mean duration of
exposure to LDX was 555.3 days (SD 253.50). Further
information on dosing is provided in ESM 1.
3.3 Treatment-Emergent Adverse Events (TEAEs)
TEAEs were reported in 89.8% of participants, with most
reported as mild (n = 112 [35.7%]) or moderate (n = 133
[42.4%]) (Table 2 and ESM 1, Table S2). No deaths were
reported during the study. The overall proportion of par-
ticipants experiencing TEAEs, and the frequency of
commonly reported TEAEs, was generally similar in
children and adolescents (ESM 1, Table S3). The pro-
portion of participants reporting TEAEs was generally
higher among those receiving higher doses of LDX (ESM
1, Table S3).
In total, 36 serious TEAEs were reported in 28 partici-
pants, four of which were considered by the investigator to
be related to LDX (three syncope events and one severe
arrhythmia event) (ESM 1, Table S4). Serious TEAEs
reported in more than one participant were syncope (n = 6,
seven events), appendicitis (n = 3, three events), and
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pyelonephritis (n = 2, two events). One syncope event was
recorded as severe and related to LDX treatment and
resulted in treatment interruption. The remaining six syn-
cope events did not result in treatment interruption and
were recorded as moderate (n = 4, two events considered
related to LDX) or mild (n = 2) in intensity. All syncope
events resolved without pharmacological intervention. The
arrhythmia event was considered to be related to a pre-
existing heart defect (patent foramen ovale) that was
unknown at screening (ESM 1, Table S4).
TEAEs resulted in early discontinuation from the study
for 39 (12.4%) participants; of these, two TEAEs were
recorded as serious: arrhythmia (n = 1) and suicide
attempt (n = 1; described in Sect. 3.4) (ESM 1, Tables S4
and S5). The most commonly reported TEAEs leading to
discontinuation were decreased appetite (n = 7 [2.2%]),
drug ineffective (n = 6 [1.9%]), depressed mood (n = 4
[1.3%]), irritability (n = 4 [1.3%]), tic (n = 3 [1.0%]),
insomnia (n = 3 [1.0%]), aggression (n = 2 [0.6%]),
apathy (n = 2 [0.6%]), tachycardia (n = 2 [0.6%]), and
weight decrease (n = 2 [0.6%]). Five additional patients
discontinued because of investigator-perceived lack of
efficacy; according to the protocol, these should have been
recorded as TEAEs.
3.4 TEAEs of Special Interest
Based on their reported association with stimulant treat-
ment, decreased appetite, weight decrease, insomnia,
headache, and psychiatric TEAEs were pre-selected as
being of special interest in this study [17]. Of these,
decreased appetite and weight decrease were reported by
54.1 and 20.1% of participants, respectively (Table 2). Of
the 170 participants who reported decreased appetite,
28.2% also experienced weight decrease TEAEs (details of
actual weight changes are presented in Sect. 3.6). The
incidence of reported decreased appetite and weight
decrease TEAEs peaked at weeks 1 and 12, respectively,
and declined thereafter (Fig. 3a, b). The median time to the
first report of decreased appetite was 13.5 days (range
1–653), and the median duration was 169.0 days (range
1–749). For weight decrease TEAEs, the median time to
first report was 29.0 days (range 1–677), with a median
duration of 225.0 days (range 26–724). Most decreased
appetite (210/214) and weight decrease (66/68) TEAEs
were rated as being mild or moderate in severity. The dose
of LDX was adjusted as a result of decreased appetite or
weight decrease TEAEs in 14.9 and 17.6% of cases,
respectively. Seven participants discontinued the study
Enrolled from previous
LDX study (n = 124) 
Directly enrolled
(n = 190) 
Total enrolled
(N = 314) 
Safety populationa
(N = 314) 
Full analysis setb
(N = 299) 
Completed study
(n = 191)c 
Discontinued
(n = 123)
• Adverse event (39)
• Protocol deviation (4)
• Withdrawal by participant (41)
• Lost to follow-up (5)
• Lack of efficacyd (5)
• Other (29)
Excluded from FAS
(n = 15)
• Lack of post-baseline 
 efficacy assessment (1)
• Violation of Good 
 Clinical Practice (14)
Fig. 2 Patient disposition. aThe safety population comprised all
enrolled participants who received at least one dose of LDX during
the study. bThe FAS comprised all participants who received one dose
of LDX and had at least one on-treatment post-baseline efficacy
assessment; all 14 participants from a single study site were excluded
from the efficacy analyses because of a serious violation of Good
Clinical Practice. cThe number of participants refers to individuals in
the enrolled population who completed the study. A total of 191
participants who were included in the FAS completed the study.
dAccording to the protocol, lack of efficacy (in the opinion of the
investigator) was to be reported as an adverse event. Five additional
patients discontinued because of investigator-perceived lack of
efficacy; according to the protocol, these should have been recorded
as treatment-emergent adverse events. FAS full analysis set, LDX
lisdexamfetamine dimesylate
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because of decreased appetite, and two discontinued as a
result of weight decrease. At the end of the study, 24.3% of
decreased appetite and 17.6% of weight decrease TEAEs
were ongoing.
In total, 124 insomnia TEAEs (75 insomnia events, 46
initial insomnia events, two middle insomnia events, one
terminal insomnia event) were reported in 98 (31.2%) par-
ticipants. The median time to first report was 17.0 days
(range 1–729), and themedian durationwas 42.8 days (range
1–739). The incidence of insomnia TEAEs peaked at week 1
and then rapidly decreased (Fig. 3c). Most insomnia TEAEs
(122/124) were mild or moderate; the dose of LDX required
adjustment in 15.3% of cases. Four patients discontinued
because of insomnia TEAEs. At the end of the study, 17
insomnia events (13.7%) were ongoing.
Of 139 headache TEAEs reported in 68 participants
(21.7%), two were severe in intensity. The incidence of
headache was highest at week 1, decreased by week 2, and
remained stable at subsequent visits (Fig. 3d). The median
time to the first reported headache was 22.0 days (range
1–718), and the median duration was 2.0 days (range
1–729). The dose of LDX remained unchanged in 97.8% of
cases of headache. One patient discontinued as a result of
headache, and one (0.7%) headache event was ongoing at
the end of the study.
Psychiatric TEAEs of special interest were psychosis
and mania (n = 1), suicidal events (suicidal ideation,
n = 2; suicide attempt, n = 1), and aggression events
(aggression, n = 14; anger, n = 2; hostility, n = 1). The
suicide attempt was reported as a serious, severe AE. No
medical event occurred, no treatment was given, and the
event resolved on the same day. The suicide attempt was
considered by the investigator to be not related to LDX
treatment; however, LDX was discontinued (ESM 1,
Table S2). The time-course of psychiatric TEAEs was not
assessed.
3.5 Vital Signs and Electrocardiogram Parameters
LDX treatment was associated with increases from base-
line to LOTA in mean pulse rate (7.0 bpm [95% confidence
interval [CI] 5.7–8.2]; range -32 to ?41), SBP (3.4 mmHg
[95% CI 2.2–4.5]; range -26 to ?40), and DBP
(3.2 mmHg [95% CI 2.2–4.2]; range -24 to ?25). Fol-
lowing commencement of LDX treatment, means for pulse
rate, SBP, and DBP gradually increased before reaching a
plateau at approximately week 36, 60, and 24, respectively
(ESM 1, Fig. S1). Based on pre-specified thresholds, PCI
high pulse rates (C110 bpm) were observed in 22 (7.0%)
participants, four of whom met this PCI criterion at more
Table 1 Baseline
demographics and disease
characteristics (safety
population)
Characteristic Safety population (N = 314)
Demographics
Age, years 11.4 ± 2.88 (6–19)a
6–12 202 (64.3)
13–17a 112 (35.7)
Sex, male 250 (79.6)
Race, White 310 (98.7)
Body mass index, kg/m2b 19.22 ± 3.389 (13.0–29.8)
Participants who received at least one previous ADHD medication 271 (86.3)
Disease characteristics
ADHD subtype
Combined 251 (79.9)
Predominantly inattentive 56 (17.8)
Predominantly hyperactive-impulsive 7 (2.2)
ADHD-RS-IV total score 41.1 ± 7.03 (17–54)c
Inattention subscale score 22.1 ± 3.52 (11–27)
Hyperactivity/impulsivity subscale score 19.0 ± 5.86 (2–27)
Data are presented as n (%) or mean ± SD (range)
ADHD attention-deficit/hyperactivity disorder, ADHD-RS-IV ADHD Rating Scale IV, LDX lisdexamfe-
tamine dimesylate, SD standard deviation
a Four participants were aged[17 years at baseline and were included in the age category 13–17 years.
These participants were enrolled because, for study eligibility purposes only, age was based on age at the
time of consent for this study or for the previous LDX study if applicable
b Calculated at screening
c One participant had a score of 17, which was lower than the protocol-specified value of C 28; this was
recorded as a protocol deviation/violation
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than one post-baseline visit. PCI high SBP readings
(C125 mmHg in children and C135 mmHg in adolescents)
were recorded in 45 children (22.4%; 23 at more than one
post-baseline visit) and 17 adolescents (15.2%; seven at
more than one post-baseline visit). PCI high DBP readings
(C80 mmHg in children and C85 mmHg in adolescents)
Table 2 Treatment-emergent
adverse events (safety
population)
TEAE—preferred term Safety population (N = 314)
Participants Events
Any TEAE 282 (89.8) 1803
Severe TEAEa 37 (11.8) 52
Serious TEAEb 28 (8.9) 36
TEAEs considered related to study drugc 232 (73.9) 785
TEAEs leading to treatment discontinuation 39 (12.4) 59
TEAEs resulting in death 0 0
TEAEs reported in C5% of participants
Decreased appetite 170 (54.1) 214
Nasopharyngitis 73 (23.2) 129
Headache 68 (21.7) 139
Weight decrease 63 (20.1) 68
Insomnia 60 (19.1) 75
Initial insomnia 38 (12.1) 46
Irritability 36 (11.5) 39
Pyrexia 32 (10.2) 41
Nausea 31 (9.9) 41
Abdominal pain 30 (9.6) 38
Abdominal pain upper 28 (8.9) 34
Vomiting 27 (8.6) 33
Cough 22 (7.0) 25
Depressed mood 19 (6.1) 20
Gastroenteritis 18 (5.7) 21
Oropharyngeal pain 18 (5.7) 24
Tic 18 (5.7) 25
Pharyngitis 16 (5.1) 18
TEAEs considered related to study drug reported in C5% of patientsc
Decreased appetite 155 (49.4)
Weight decreased 57 (18.2)
Insomnia 41 (13.1)
Initial insomnia 28 (8.9)
Irritability 27 (8.6)
Nausea 21 (6.7)
Headache 18 (5.7)
Tic 16 (5.1)
Data are presented as n or n (%)
LDX lisdexamfetamine dimesylate, TEAE treatment-emergent adverse event
a A severe TEAE was defined as an adverse event that interrupted usual activities of daily living, sig-
nificantly affected clinical status, or may require intensive therapeutic intervention
b A serious TEAE was defined as any untoward medical occurrence that resulted in death, was life-
threatening, required inpatient hospitalization or prolonged existing hospitalization, resulted in persistent or
significant disability/incapacity, was a congenital abnormality/birth defect, or was an important medical
event. Important medical events may have been considered as serious TEAEs when, based upon medical
judgement, they may have jeopardized the patient and may have required medical or surgical intervention
to prevent one of the outcomes listed above. Any new onset of seizures, syncope, or loss of consciousness
was required by the sponsor to be reported as a serious TEAE
c As determined by the investigator
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were recorded in 78 children (38.8%) and 24 adolescents
(21.4%), with 49 children and nine adolescents meeting the
criterion at more than one post-baseline visit. Additional
data regarding participants meeting pre- and post hoc-de-
fined PCI thresholds for pulse, SBP, and DBP are reported
in ESM 1, Table S6. The mean QTcF decreased from
baseline to LOTA (-0.6 ms [95% CI -2.3 to 1.2]; range
-50 to ?53), and a PCI high QTcF interval (C450 ms)
was recorded for one participant. Mean changes from
baseline and proportions of participants meeting PCI
thresholds for additional ECG parameters are reported in
ESM 1, Tables S7 and S8.
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3.6 Weight, Height, and Body Mass Index
From baseline to LOTA, a mean increase in weight (2.1 kg
[95% CI 1.5–2.8]; range -20 to ?34), and height (6.1 cm
[95% CI 5.6–6.7]; range -1 to ?20), and a mean decrease
in BMI (-0.5 kg/m2 [95% CI -0.7 to -0.3]; range -7 to
?10) was observed. Z-scores for weight, height, and BMI
were within 1 SD of the mean (C-1 and\1) at baseline for
197 (62.7%), 169 (53.8%), and 193 (61.5%) participants,
respectively, and at LOTA for 210 (67.1%), 180 (59.8%),
and 189 (60.4%) participants, respectively. However, there
was a general shift to lower z score categories for height,
weight, and BMI from baseline to LOTA (ESM 1,
Table S9). A PCI decrease or increase in body weight
(change of C7% from baseline) was reported overall in 112
(35.8%) and 129 (41.2%) participants, respectively, at
baseline and in 33 (10.5%) and 119 (38.0%) participants,
respectively, at LOTA. More in-depth analyses of growth
over the 2-year study period, in addition to measures of
sexual maturation, will be the subject of future
investigations.
3.7 Psychiatric Assessments
Mean BPRS-C scores decreased (indicating improvement)
from baseline (19.1 [SD 11.14]) to week 4 (8.4 [SD 7.52])
and then remained stable to the end of the study (week 104;
7.1 [SD 7.12]). At LOTA, the mean change from baseline
in BPRS-C total score was -10.3 (SD 9.64). BPRS-C item
6 (suicidal ideation—thoughts, threats, or attempts of sui-
cide) and item 9 (hallucinations—visual, auditory, or other
hallucinatory experiences or perceptions) were considered
of particular interest. Responses to item 6 were reported as
moderately severe in two participants, neither of whom had
a reported TEAE of suicidal ideation. In a third participant,
the response to item 6 was reported as extremely severe;
this participant had a suicide attempt reported as a serious
severe TEAE (ESM 1, Tables S2 and S4). No responses of
moderately severe, severe, or extremely severe were
reported on item 9 of the BPRS-C.
Using the C-SSRS, suicidal ideation was reported in
seven participants at any post-baseline visit (two partici-
pants at visit 4, two at visit 5, two at visit 7, and one
participant at early termination [day 61]), two of whom
also reported suicidal behavior (ESM 1, Tables S10 and
S11). One participant reported suicidal behavior at their
early termination visit. This individual, who had no pre-
vious positive responses reported on the C-SSRS, reported
an actual suicide attempt, an interrupted attempt, and the
presence of suicidal behavior in addition to an inaccurate
report of a completed suicide; this was the same participant
who had a suicide attempt reported as a serious severe
TEAE (described in Sect. 3.4).
In the second participant, who also reported a TEAE of
suicidal ideation, the reported suicide attempt was con-
sidered erroneous; this patient self-inflicted a superficial
scratch that the patient knew was not dangerous (ESM 1,
Table S10). A single participant reported non-suicidal self-
injurious behavior on the C-SSRS. In total, across all three
measures of psychiatric safety used (TEAE reporting,
BPRS-C, and C-SSRS), nine participants reported suicidal
ideation and/or behavior on one or more measures.
3.8 Efficacy
3.8.1 Attention-Deficit/Hyperactivity Disorder Rating
Scale IV Total and Subscale Scores
In the FAS, the baseline mean ADHD-RS-IV total score
was 41.2 (SD 7.01) and the mean scores for the subscales
hyperactivity/impulsivity and inattention were 19.0 (SD
5.89) and 22.1 (SD 3.46), respectively. Total and subscale
scores decreased from baseline to week 4 (total, 16.6 [SD
9.94]; hyperactivity/impulsivity, 7.4 [SD 5.47]; inattention,
9.2 [SD 5.70]) and then continued to decrease gradually
before stabilizing at approximately week 48 (total, 13.9
[SD 8.95]; hyperactivity/impulsivity, 5.8 [SD 4.88]; inat-
tention, 8.1 [SD 5.32]) (Fig. 4). At week 104, the mean
ADHD-RS-IV total score was 12.8 [SD 8.47] and hyper-
activity/impulsivity and inattention subscale scores were
5.0 (SD 4.53) and 7.8 (SD 5.08), respectively. The mean
change from baseline to LOTA in ADHD-RS-IV total
score and hyperactivity/impulsivity and inattention sub-
scale scores was -25.8 (95% CI -27.0 to -24.5), -12.6
(95% CI -13.4 to -11.9), and -13.1 (95% CI -13.8 to
-12.4), respectively (all p\ 0.001).
3.8.2 Clinical Global Impressions-Improvement Scale
The proportion of participants categorized as improved
based on a CGI-I score of 1 (very much improved) or 2
(much improved) increased from 42.3% at week 1 to
83.0% at week 4 and remained above 80% for the
remainder of the study (week 104; 89.1%). At LOTA, 233
of 299 (77.9%) participants were improved based on CGI-I
scores (141 participants [47.2%] very much improved and
92 [30.8%] much improved).
3.8.3 Responder Analyses
Based on both of the definitions of clinically relevant
response, the proportion of treatment responders increased
during weeks 1–4 and then continued to increase steadily
before stabilizing at approximately week 72 (ESM 1,
Fig. S2). At LOTA, 77.3% of participants had a reduction
of at least 30% in ADHD-RS-IV total score from baseline
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and a CGI-I score of 1 or 2, and 69.2% had a reduction of at
least 50% in ADHD-RS-IV total score from baseline and a
CGI-I score of 1 or 2.
4 Discussion
ADHD is increasingly recognized as a persistent disorder
requiring long-term management [21, 32]. Stimulants are
the cornerstone of ADHD pharmacotherapy, and their
safety has been characterized in numerous clinical trials
[7, 11–16]. However, the short duration of most previous
trials limits their value in understanding the longer-term
safety of these medications. Here, we report data from the
longest safety and efficacy study to date of the prodrug
stimulant LDX.
Several aspects of the study design should be considered
when interpreting the findings presented here. Strengths of
the study include the 2-year duration, the large number of
participants enrolled at multiple sites across Europe, and
the extensive safety assessments. Limitations include the
open-label design and the lack of a placebo control arm,
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which limit interpretation of results. Individuals with a
comorbid psychiatric diagnosis were excluded, which may
limit applicability to patient populations seen in clinical
practice. In addition, a sizeable proportion of participants
(39.5%) were recruited from antecedent studies, which
may have enriched the study population with individuals
who tolerated LDX. In previous open-label LDX studies of
6–12 months’ duration, substantially higher proportions of
patients were recruited from antecedent studies (86–100%)
[18–20, 23]. However, this enriched population does reflect
the patients who would be expected to receive long-term
LDX treatment in clinical practice, because patients who
do not tolerate a medication are much less likely to remain
on it long term. Finally, patients were excluded if they were
well-managed on their existing medication. While this may
have influenced the findings, this study population does
reflect patients likely to receive LDX in clinical practice,
particularly in Europe where LDX is licensed as a second-
line treatment in children and adolescents [33].
In SPD489-404, 89.8% of participants receiving LDX
reported at least one TEAE, with most reported as mild
(35.7%) or moderate (42.4%). Despite its longer duration,
the incidence of TEAEs in the present 2-year study was
similar to that observed in previously reported open-label
studies of 6–12 months’ duration (78–88%) [18–20, 23]
and only slightly greater than observed in the LDX treat-
ment arms of randomized controlled trials of 4–9 weeks’
duration (69–79%) [11, 13–15, 22, 34]. These results
suggest that the relationship between the incidence of
TEAEs is not linearly related to the duration of LDX
treatment. The incidence of serious TEAEs was modest
(8.9%; 4 of 36 serious events were considered related to
LDX) despite the length of the study and the sponsor’s
requirement to record any onset of seizures, loss of con-
sciousness, or syncope as a serious event. These findings
are consistent with previous 2-year open-label studies of
stimulant medications in children with ADHD [35, 36]. In
a study of extended-release amphetamines, 92% of children
reported at least one TEAE, 3% reported serious TEAEs,
and 15% discontinued the study as a result of TEAEs [35].
Similarly, 89.2% of children reported at least one TEAE in
a 2-year study of osmotic-release oral system methylphe-
nidate and 7.6% discontinued as a result of TEAEs; the
number of serious TEAEs was not reported [36].
The TEAEs most frequently reported by clinical trial
participants receiving ADHD stimulant medications
included decreased appetite, weight decrease, insomnia,
and headache; these were identified as TEAEs of special
interest for the present study. Over the 2-year duration of
the study, decreased appetite was the most common
TEAE, reported in over 50% of participants (in the 14.1
version of MedDRA, the term ‘‘decreased appetite’’
incorporates reports that would have been labelled as
‘‘anorexia’’ in previous versions), and weight decrease
was reported as a TEAE for approximately 20% of par-
ticipants. This compares with reports of decreased appe-
tite, anorexia, and weight decrease TEAEs in 21–33,
\5–15, and 16–18% of participants, respectively, in
previous LDX studies of 6–12 months’ duration
[18, 20, 23]. In addition to cases of weight decrease
reported as TEAEs, assessment of all participants’ weight
revealed that, although mean weight increased over the
course of the study, z scores for weight and BMI did
decrease (as did z scores for height), and approximately
one-third of participants reported a decrease in weight of
PCI. Relative losses in weight, height, and BMI, and
slowing down in growth, compared with population
norms, were observed previously in children with ADHD
receiving LDX for 15 months [37]. Similarly, at the
3-year follow-up of the National Institute of Mental
Health Multimodal Treatment Study of ADHD, methyl-
phenidate-treated children were 2.7 kg lighter than un-
medicated controls, with the greatest reductions in growth
velocity occurring in the first year of treatment [38].
Clinical practice guidelines recommend the ongoing
monitoring of height and weight in pediatric patients
receiving stimulant ADHD therapies [21], and the effects
of long-term LDX treatment on weight, growth, and
maturation in study SPD489-404 will be the focus of
further detailed analyses.
To avoid dilution of any association of LDX with sleep
difficulties, multiple MedDRA terms related to sleep
TEAEs (insomnia, initial insomnia, middle insomnia, and
terminal insomnia) were combined and analyzed as a single
group. When aggregated, insomnia events were reported in
approximately 30% of participants. While the incidence of
insomnia TEAEs in LDX trials based on aggregated terms
has not previously been reported, the single term ‘‘insom-
nia’’ was reported in 12–17% of children and adolescents
in long-term studies [18, 20, 23]. Although stimulants have
often been associated with disturbed sleep, the relationship
between ADHD, stimulant medications, and sleep is not
straightforward. Indeed, ADHD itself is reported to be
associated with sleep disturbances [39], and while some
data suggest stimulants can have a negative impact on
sleep, other data also indicate that some patients may
experience no impact, or even a positive impact, on sleep
[40–43].
Currently, few data have been published describing the
time-course of TEAEs during prolonged stimulant expo-
sure. In SPD489-404, the emergence and duration of
TEAEs of special interest were monitored throughout the
2-year study. The incidence of decreased appetite, weight
decrease, insomnia, and headache TEAEs peaked early in
the study, and the median duration of events ranged from 2
to 225 days. For all TEAEs of special interest, most cases
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had resolved by the conclusion of the study. This is con-
sistent with the previous observation that overall rates of
TEAEs were similar in LDX clinical trials of varying
duration (as previously discussed). These results confirm
those of a 12-month open-label study of LDX in children
and a 12-month study of LDX in adults [18, 19]. Further-
more, a 24-month open-label study of extended-release
amphetamines in children with ADHD revealed that over
50% of all TEAEs were reported during the first 6 months
of the study [35]. While these findings may suggest an
adaptation to LDX-induced TEAEs over time, the possi-
bility of participant withdrawal for reasons of poor toler-
ability leading to the gradual enrichment of the study
population with individuals with good tolerability to LDX
cannot be excluded. In addition, some individuals did
experience TEAEs that did not start until late in the study,
or that continued over long periods of time, highlighting
the importance of careful dose titration and individualized
and ongoing patient management.
Typical of stimulant ADHD medications, prescribing
information for LDX warns of the risk of serious cardiovas-
cular reactions, including sudden death, and recommends that
its use is avoided in individuals with pre-existing cardiac
abnormalities [33, 44]. In addition, clinical practice guidelines
recommend that patients receiving stimulants are regularly
monitored for cardiovascular changes [21]. However, large-
scale epidemiological studies have not established a strong
link between stimulant medications and an increase in the risk
of serious cardiac events [45–47]. Cardiovascular-related
TEAEs were uncommon in SPD489-404, although increases
in mean pulse and blood pressure were observed. The pro-
portion of participants who exceeded pre-specified PCI
thresholds ranged from 7.0% (for pulse rate) to 38.8% (for
DBP in children), demonstrating that some participants did
experience substantial and PCI changes. In many cases, PCI
criteria were met at only one post-baseline visit, suggesting
that the eventwas transitory rather than indicative ofpersistent
elevation. Considering the numbers of participants meeting
PCI thresholds and the reported range of the mean changes in
vital signs, it is perhaps unexpected that clinicians reported so
few TEAEs related to changes in blood pressure or heart rate.
Symptomatic improvements were demonstrated
throughout this 2-year open-label study, indicating that the
efficacy of LDX is maintained in the long term. Symptoms
improved rapidly over the first 4 weeks of the study, with a
slower rate of improvement observed thereafter. Based on
responder analyses, the majority of individuals experienced
improvements in symptoms that are likely to be clinically
meaningful. Notably, the degree of improvement, based on
ADHD-RS-IV and/or CGI-I scores, was similar to that
observed in several double-blind, placebo-controlled trials
[13–15].
5 Conclusions
This is the first 2-year study of LDX, and the findings
represent an important addition to the pool of long-term
clinical data available to enable accurate and informed
treatment choices for children and adolescents with
ADHD. TEAEs were as expected for the stimulant class of
ADHD medication, with decreased appetite, weight
decrease, insomnia, and headache among the most com-
monly reported. Detailed analyses of the incidence and
time-course of these commonly reported TEAEs indicated
that they peaked early in the study and declined thereafter.
Some individuals did experience potentially clinically
significant changes in cardiovascular parameters or weight,
supporting the recommendations for regular monitoring of
patients in clinical practice [21]. LDX treatment was
associated with symptomatic improvements that were
observed for the 2-year duration of the study.
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